This CPB has been revised to add the following medical necessity criteria for anakinra (Kineret) therapy: (i) for initial approval, added requirement that member be tested for biomarkers Rheumatoid Factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) and the test was positive [or tested for RF, anti-CCP, and c-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)] if the member has no prior biologic or targeted synthetic DMARD use in rheumatoid arthritis (RA), and (ii) for continuation criteria, added specific continuation requirements that reflect a positive response to therapy for RA, AOSD, SJIA, NOMID, and recurrent pericarditis. This CPB has been updated with the following: (i) updated the TB nomenclature, and (ii) updated the table in the appendix for brands of targeted immune modulators and FDA-approved indications.